about
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.Neuroleptics in headache.Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder.Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Female sexual disorders: psychiatric aspects.The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women.The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions.Osteoporosis screening and treatment in women with schizophrenia: a controlled study.A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case reportRegarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophreniaProlactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose studyThe Effects of Antipsychotics on Prolactin Levels and Women's Menstruation.Hormone profile in acute psychotic disorders: A cross-sectional comparison of serum hormone concentrations in treated and untreated male patients with schizophrenia.Sertraline Induced Galactorrhea.A systematic review of instruments to measure sexual functioning in patients using antipsychotics.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Prolactin, testosterone and cortisol as possible markers of changes in cardiovascular function associated with urbanization.Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat.The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager).Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model.Erectile dysfunction in a sample of patients attending a psychiatric outpatient department.Attitudes toward menstruation in females with schizophrenia or schizoaffective disorders in Taiwan.Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia
P2860
Q31980098-FCEA2117-000C-43BD-9A7A-34B4B5EB074EQ33223628-537EA774-1056-4803-A5B9-58C7B80C8169Q33619940-51A57521-8E6B-4DCA-92D4-82200507E8CDQ33738740-46232F73-E534-4297-999B-E56799A58DA0Q34230366-8383F8DB-41A6-4BB4-B5AC-0DF921E30BDBQ34412065-C9CBC708-7E6A-4908-A592-DF07D8BD8187Q34455825-21967506-096A-44CE-B40C-9C31023D18C2Q34544811-29E549BD-C9B1-4956-B8D4-D4B72243FEC2Q34640811-AA66CBBA-9F1D-471A-AB2C-27F75CBD939AQ34708405-7CC0F8F2-CF4F-478E-A6B1-1D216EF4CEDAQ34708414-6D6E3772-3CA2-4A81-9FCC-5FA26675CDB1Q35369968-A98521A5-CEA8-460E-A22B-A81D159C64E7Q35680852-A59ED95E-BBA1-4FF6-AC9F-4419B6A5ACFAQ35751533-1FA48324-FF5F-4915-8989-EE1FF4B8F6CDQ36322256-B45337B3-1A88-4BDF-833A-53A2AB3EEE41Q36737420-EFAC3BC7-F7C9-4048-8069-6526AF755237Q36836750-E816D8BE-DB2E-4A14-992B-727C826E889BQ37138734-490F5170-D1AE-4C51-90B5-BA3CA16C2B36Q37456024-69C6A7C7-04F1-4C5E-A2CD-A776713948CCQ37663522-6A366A02-0B29-4D1C-957F-C960D31B2D9FQ37704057-B1A30E5F-4016-4144-8B95-0E747D447989Q38206238-8417D043-013E-4672-B4C9-5A42C408B70FQ38778145-28791A7D-58ED-43F6-8BDA-688E07B2606DQ39639409-E1CA48A9-911D-45BE-BFE9-68E857EA1DE4Q43608200-EC3B1F38-0E24-4F50-B0E7-8FF5B9873349Q44983975-0CDA2F49-99B6-4007-ABD9-38E8A2BB6EC4Q46029590-2ECC2DC8-0923-4BD4-9E9B-9D5BCCBF2565Q46650329-CD70B132-F591-44F3-9F5A-C2671DDB06E5Q46886132-899227F9-020B-4C65-98EE-68E23E39873AQ46917137-2889C998-70F0-4643-ACAE-EE071E6D4017Q50609675-6613404A-F347-4692-B272-FA90B8AACBF3Q51292022-24396A71-918A-4C90-8B89-99503A3F53E6Q57820223-61F70E6C-2B1F-4994-8619-F6DC1D034DB9
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Neuroleptic-induced hyperprolactinemia.
@ast
Neuroleptic-induced hyperprolactinemia.
@en
Neuroleptic-induced hyperprolactinemia.
@nl
type
label
Neuroleptic-induced hyperprolactinemia.
@ast
Neuroleptic-induced hyperprolactinemia.
@en
Neuroleptic-induced hyperprolactinemia.
@nl
prefLabel
Neuroleptic-induced hyperprolactinemia.
@ast
Neuroleptic-induced hyperprolactinemia.
@en
Neuroleptic-induced hyperprolactinemia.
@nl
P1476
Neuroleptic-induced hyperprolactinemia.
@en
P2093
R A Dickson
W M Glazer
P304
P356
10.1016/S0920-9964(98)00159-5
P407
P478
P577
1999-03-01T00:00:00Z